European CHMP recommends approval of evinacumab (Evkeeza) for treatment of adults and adolescents with homozygous familial hypercholesterolaemia

Evinacumab is a monoclonal antibody which reduces LDL-C cholesterol (LDL-C) level independent of the presence of the LDL receptor and will be licensed as an adjunct to diet and other LDL-C lowering therapies.

European Medicines Agency